Literature DB >> 33717091

Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese.

Xiaosheng Huang1,2, Xinhua Liu1,2, Ye Ye2, Tong Zhang1, Shaoyi Mei1,2, Tianhui Zhu1,2, Shiming Peng1,2, Jiamin Cai2, Zonghui Yan1,2, Kun Zeng1,2, Danyao Nie1,2, Liangnan Sun1,2, Xiaofeng Hou1, Jun Zhao3.   

Abstract

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are well-known key immune checkpoints that play a crucial dampening effect on regulating T-cell homeostasis and self-tolerance. In this study, we aimed to evaluate the association between immune checkpoints (CTLA-4 and PD-1) and Posner-Schlossman syndrome (PSS) in a southern Chinese population. A total of 137 patients with PSS and 139 healthy controls from a southern Chinese population were recruited. Five single nucleotide polymorphisms (SNPs) of CTLA-4 (rs733618, rs4553808, rs5742909, rs231775, and rs3087243) and five SNPs of PD-1 (rs10204525, rs2227981, rs2227982, rs41386349, and rs36084323) were genotyped by SNaPshot technique. Soluble CTLA-4 (sCTLA-4) and soluble PD-1 (sPD-1) were determined by ELISA and antibody array assay, respectively. The frequencies of T allele at rs733618 and A allele at rs231775 of CTLA-4 were significantly higher in PSS patients than in healthy controls (corrected p (Pc ) = 0.037; Pc = 0.044, respectively). The haplotype frequencies of CACGG haplotype (rs733618-rs4553808-rs5742909-rs231775-rs3087243) of CTLA-4 and TGAGC haplotype (rs10204525-rs2227981-rs2227982-rs41386349-rs36084323) of PD-1 in the PSS group was significantly lower than those in the control group (Pc = 0.015, p = 0.034, respectively). Circulating plasma levels of sCTLA-4 and sPD-1 in PSS patients were significantly higher than those in controls (all p < 0.001). The present study suggests that CTLA-4 and PD-1 genetic polymorphisms are associated with the susceptibility to PSS in a southern Chinese population. The upregulated circulating plasma protein levels of sCTLA-4 and sPD-1 might provide some hints regarding the dysfunction of immune checkpoints in PSS during the active status.
Copyright © 2021 Huang, Liu, Ye, Zhang, Mei, Zhu, Peng, Cai, Yan, Zeng, Nie, Sun, Hou and Zhao.

Entities:  

Keywords:  CTLA-4; PD-1; Posner-Schlossman syndrome; genetic variants; soluble molecular

Mesh:

Substances:

Year:  2021        PMID: 33717091      PMCID: PMC7943469          DOI: 10.3389/fimmu.2021.607966

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  35 in total

1.  CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.

Authors:  Qianli Meng; Peizeng Yang; Bing Li; Hongyan Zhou; Xiangkun Huang; Lianxiang Zhu; Yalin Ren; Aize Kijlstra
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-10       Impact factor: 4.799

2.  A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation.

Authors:  Mathias Mäurer; Silke Loserth; Annette Kolb-Mäurer; Anke Ponath; Stefan Wiese; Niels Kruse; Peter Rieckmann
Journal:  Immunogenetics       Date:  2002-03-12       Impact factor: 2.846

3.  Meta-analysis of association between the +49A/G polymorphism of cytotoxic T-lymphocyte antigen-4 and thyroid associated ophthalmopathy.

Authors:  Hao Wang; Li-Shuang Zhu; Jin-Wei Cheng; Ji-Ping Cai; You Li; Xiao-Ye Ma; Rui-Li Wei
Journal:  Curr Eye Res       Date:  2015-01-23       Impact factor: 2.424

4.  Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence.

Authors:  Xiong-Biao Wang; Maria Kakoulidou; Ricardo Giscombe; Qianhui Qiu; DeRen Huang; Ritva Pirskanen; Ann Kari Lefvert
Journal:  J Neuroimmunol       Date:  2002-09       Impact factor: 3.478

5.  Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer.

Authors:  Tong Sun; Yifeng Zhou; Ming Yang; Zhibin Hu; Wen Tan; Xiaohong Han; Yuankai Shi; Jiarui Yao; Yongli Guo; Dianke Yu; Tian Tian; Xiaoyi Zhou; Hongbing Shen; Dongxin Lin
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

6.  Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis.

Authors:  X B Wang; R Pirskanen; R Giscombe; A K Lefvert
Journal:  J Intern Med       Date:  2008-01       Impact factor: 8.989

7.  Characteristics of cases needing advanced treatment for intractable Posner-Schlossman syndrome.

Authors:  Kazuichi Maruyama; Yuko Maruyama; Sunao Sugita; Kazuhiko Mori; Yu Yokoyama; Shiho Sanuki-Kunimatsu; Hiroko Nakagawa; Shigeru Kinoshita; Manabu Mochizuki; Toru Nakazawa
Journal:  BMC Ophthalmol       Date:  2017-04-11       Impact factor: 2.209

8.  The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.

Authors:  Boyang Chang; Tao Huang; Huajun Wei; Lujun Shen; Duo Zhu; Wenjun He; Qifeng Chen; Huihua Zhang; Yunjian Li; Ruopan Huang; Wang Li; Peihong Wu
Journal:  Cancer Immunol Immunother       Date:  2018-12-01       Impact factor: 6.968

9.  PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome.

Authors:  Qianli Meng; Xiaoli Liu; Peizeng Yang; Shengping Hou; Liping Du; Hongyan Zhou; Aize Kijlstra
Journal:  Mol Vis       Date:  2009-02-20       Impact factor: 2.367

10.  The soluble isoform of CTLA-4 as a regulator of T-cell responses.

Authors:  Frank J Ward; Lekh N Dahal; Subadra K Wijesekera; Sultan K Abdul-Jawad; Taniya Kaewarpai; Heping Xu; Mark A Vickers; Robert N Barker
Journal:  Eur J Immunol       Date:  2013-03-06       Impact factor: 5.532

View more
  1 in total

Review 1.  Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.

Authors:  Mengke Niu; Yiming Liu; Ming Yi; Dechao Jiao; Kongming Wu
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.